Walleye Capital
ACAD icon

Walleye Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Walleye Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Buy
9,700
+4,600
+90% +$110K ﹤0.01% 3297
2025
Q4 		$136K Buy
+5,100
New +$122K ﹤0.01% 3736
2024
Q3 		– Sell
-30,900
Closed -$502K – 5189
2024
Q2 		$502K Buy
30,900
+20,100
+186% +$324K ﹤0.01% 3511
2024
Q1 		$200K Buy
10,800
+10,600
+5,300% +$263K ﹤0.01% 3981
2023
Q4 		$6.26K Sell
200
-4,200
-95% -$100K ﹤0.01% 4624
2023
Q3 		$91.7K Buy
+4,400
New +$120K ﹤0.01% 3976
2023
Q1 		– Sell
-6,100
Closed -$97.1K – 3867
2022
Q4 		$97.1K Sell
6,100
-4,000
-40% -$62.5K ﹤0.01% 2371
2022
Q3 		$165K Buy
+10,100
New +$164K ﹤0.01% 2212
2020
Q1 		– Sell
-22,100
Closed -$945K – 842
2019
Q4 		$945K Buy
22,100
+17,800
+414% +$774K 0.06% 440
2019
Q3 		$155K Sell
4,300
-32,100
-88% -$973K 0.01% 1290
2019
Q2 		$973K Buy
+36,400
New +$930K 0.11% 279

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Walleye Capital's ACAD Position: Q1 2026 in Review

Walleye Capital sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 8,476 shares — an estimated $203K sold.

Walleye Capital first reported a position in ACAD in Q3 2019 and held it in 20 quarters. The position peaked at $7.88M in Q1 2023. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Walleye Capital reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 8,476 Acadia Pharmaceuticals shares in Q1 2026, an estimated $203K.
  • Walleye Capital first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 20 quarters.
  • Walleye Capital's Acadia Pharmaceuticals position peaked at $7.88M in Q1 2023.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.